<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Proteome Sciences Plc — News on 6ix</title>
    <link>https://6ix.com/company/proteome-sciences-plc</link>
    <description>Latest news and press releases for Proteome Sciences Plc on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Thu, 14 May 2026 11:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/proteome-sciences-plc" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d585bdbeedb30cb6f8bce2.webp</url>
      <title>Proteome Sciences Plc</title>
      <link>https://6ix.com/company/proteome-sciences-plc</link>
    </image>
    <item>
      <title>Annual General Meeting Statement</title>
      <link>https://6ix.com/company/proteome-sciences-plc/news/annual-general-meeting-statement-18</link>
      <guid isPermaLink="true">https://6ix.com/company/proteome-sciences-plc/news/annual-general-meeting-statement-18</guid>
      <pubDate>Thu, 14 May 2026 11:00:00 GMT</pubDate>
      <description>Proteome Sciences plc reported at its Annual General Meeting that its services business is experiencing good order levels and a recovery in TMT and reagent sales in the first half of the year, following budget cuts in 2025. The company believes its significant investment over the past two years positions it well to achieve substantial returns in the growing proteomics field.
                Disclaimer*</description>
    </item>
    <item>
      <title>Final results for the year ended 31 December 2025</title>
      <link>https://6ix.com/company/proteome-sciences-plc/news/final-results-for-the-year-ended-31-december-2025-10</link>
      <guid isPermaLink="true">https://6ix.com/company/proteome-sciences-plc/news/final-results-for-the-year-ended-31-december-2025-10</guid>
      <pubDate>Wed, 15 Apr 2026 06:00:00 GMT</pubDate>
      <description>Proteome Sciences plc reported a decrease in total revenues to £3.76 million for the year ended December 31, 2025, down from £4.89 million in 2024, primarily due to a significant drop in TMT® reagent sales and royalties to £1.70 million from £4.01 million. However, proteomic services revenue more than doubled to £2.06 million from £0.87 million. The company posted a loss after tax of £3.06 million, an improvement from £3.41 million in the prior year, with cash reserves at £0.78 million. Despite </description>
    </item>
    <item>
      <title>Holding(s) in Company</title>
      <link>https://6ix.com/company/proteome-sciences-plc/news/holdings-in-company-1306</link>
      <guid isPermaLink="true">https://6ix.com/company/proteome-sciences-plc/news/holdings-in-company-1306</guid>
      <pubDate>Wed, 04 Feb 2026 11:08:00 GMT</pubDate>
      <description>Vulpes Investment Management Pte Ltd, through its Vulpes Testudo Fund and Vulpes Life Sciences Fund, has increased its stake in Proteome Sciences PLC, crossing a notification threshold on February 2, 2026. The total voting rights held now stand at 24.22%, representing 84,932,629 shares, up from a previous holding of 22.80%. This acquisition of voting rights is the sole reason for the notification, with no financial instruments involved.
                Disclaimer*</description>
    </item>
    <item>
      <title>Result of Oversubscribed Retail Offer</title>
      <link>https://6ix.com/company/proteome-sciences-plc/news/result-of-oversubscribed-retail-offer-3</link>
      <guid isPermaLink="true">https://6ix.com/company/proteome-sciences-plc/news/result-of-oversubscribed-retail-offer-3</guid>
      <pubDate>Wed, 28 Jan 2026 15:31:00 GMT</pubDate>
      <description>Proteome Sciences PLC has successfully completed an oversubscribed Retail Offer, raising £132,000 through the issuance of 7,542,856 shares at 1.75 pence each, with total gross proceeds from the issue reaching £972,000. These funds, combined with proceeds from a prior fundraise, will be used to enhance TMT tag capabilities to 96X, launch new DXT isotopic plex tags, introduce novel chemoproteomic workflows, conclude a DXT license, expand San Diego operations, and provide additional working capital</description>
    </item>
    <item>
      <title>Retail Offer to raise up to £60,000</title>
      <link>https://6ix.com/company/proteome-sciences-plc/news/retail-offer-to-raise-up-to-pound60000</link>
      <guid isPermaLink="true">https://6ix.com/company/proteome-sciences-plc/news/retail-offer-to-raise-up-to-pound60000</guid>
      <pubDate>Mon, 26 Jan 2026 07:05:00 GMT</pubDate>
      <description>Proteome Sciences PLC has launched a retail offer in the UK to raise up to £60,000 by issuing up to 3,428,571 new ordinary shares at 1.75 pence per share. The net proceeds will fund advancements in TMT tag plexing, the launch of new DXT isotopic plex tags, the introduction of novel chemoproteomic workflows, a DXT licence conclusion, expansion of San Diego capacity, and additional working capital. Admission of these shares is expected on January 29, 2026, with the retail offer opening on January </description>
    </item>
    <item>
      <title>Two Further Substantial Contracts for PRM</title>
      <link>https://6ix.com/company/proteome-sciences-plc/news/two-further-substantial-contracts-for-prm</link>
      <guid isPermaLink="true">https://6ix.com/company/proteome-sciences-plc/news/two-further-substantial-contracts-for-prm</guid>
      <pubDate>Tue, 06 Jan 2026 07:00:00 GMT</pubDate>
      <description>Proteome Sciences plc has announced the securing of two substantial Good Clinical Laboratory Practice (GCLP) contracts with a combined value exceeding $1.5 million, with the majority of the work expected to be completed in 2026 and trial samples anticipated to ship in late Q1. This news follows a previous announcement and indicates strong demand from major biopharma clients in the US and Europe, contributing to a robust order book for the company throughout 2026.
                Disclaimer*</description>
    </item>
    <item>
      <title>Substantial contract for Proteome Sciences</title>
      <link>https://6ix.com/company/proteome-sciences-plc/news/substantial-contract-for-proteome-sciences</link>
      <guid isPermaLink="true">https://6ix.com/company/proteome-sciences-plc/news/substantial-contract-for-proteome-sciences</guid>
      <pubDate>Mon, 08 Dec 2025 07:00:00 GMT</pubDate>
      <description>Proteome Sciences plc has secured a significant new contract with a US biopharmaceutical company for mass spectrometry services to develop a GCLP-compliant assay for an upcoming clinical trial program slated to begin at the end of Q1 2026. A portion of this work is expected to be completed within the current financial year, with the remainder by the end of Q1 2026, mirroring the scope of previous contracts. The company anticipates further contract opportunities from this client and others in the</description>
    </item>
    <item>
      <title>Appointment of Nominated Adviser and Broker</title>
      <link>https://6ix.com/company/proteome-sciences-plc/news/appointment-of-nominated-adviser-and-broker-36</link>
      <guid isPermaLink="true">https://6ix.com/company/proteome-sciences-plc/news/appointment-of-nominated-adviser-and-broker-36</guid>
      <pubDate>Tue, 25 Nov 2025 07:00:00 GMT</pubDate>
      <description>Proteome Sciences plc has appointed SP Angel Corporate Finance LLP as its new Nominated Adviser and sole Broker, effective immediately. This announcement also includes disclosures regarding a Non-Executive Director, Roger McDowell, who was a director or partner of five companies that entered administration or liquidation proceedings between 2001 and 2015.
                Disclaimer*</description>
    </item>
    <item>
      <title>Interim Results</title>
      <link>https://6ix.com/company/proteome-sciences-plc/news/interim-results-664</link>
      <guid isPermaLink="true">https://6ix.com/company/proteome-sciences-plc/news/interim-results-664</guid>
      <pubDate>Thu, 25 Sep 2025 06:00:00 GMT</pubDate>
      <description>Proteome Sciences plc announced its interim results for the six months ended 30 June 2025. Total revenues decreased to £1.86 million from £2.22 million in H1 2024. However, proteomics services revenues increased significantly to £1.07 million, up from £0.37 million. TMT reagent sales and royalties decreased to £0.79 million compared to £1.85 million. Gross profit increased to £0.32 million from £0.20 million. The company&apos;s cost of sale and administrative costs decreased to £3.48 million from £3.</description>
    </item>
    <item>
      <title>HSBC HOLDINGS PLC ANNOUNCES RESULTS OF ITS TENDER OFFERS FOR FOUR SERIES OF NOTES</title>
      <link>https://6ix.com/company/proteome-sciences-plc/news/hsbc-holdings-plc-announces-results-of-its-tender-offers-for-four-series-of-notes-206</link>
      <guid isPermaLink="true">https://6ix.com/company/proteome-sciences-plc/news/hsbc-holdings-plc-announces-results-of-its-tender-offers-for-four-series-of-notes-206</guid>
      <pubDate>Tue, 09 Sep 2025 10:52:00 GMT</pubDate>
      <description>HSBC Holdings plc (the &apos;Company&apos;, &apos;we&apos; or &apos;us&apos;) today announces the results of its previously announced four separate offers to purchase for cash any and all of the outstanding series of notes listed in the table below. We refer to the outstanding notes listed in the table below collectively as the &apos;Notes&apos; and separately as a &apos;series&apos; of Notes. We refer to each offer to purchase a series of Notes as an &apos;Offer&apos;, and collectively as the &apos;Offers&apos;.</description>
    </item>
    <item>
      <title>Result of AGM</title>
      <link>https://6ix.com/company/proteome-sciences-plc/news/result-of-agm-1223</link>
      <guid isPermaLink="true">https://6ix.com/company/proteome-sciences-plc/news/result-of-agm-1223</guid>
      <pubDate>Fri, 16 May 2025 12:17:00 GMT</pubDate>
      <description>Result of AGM.</description>
    </item>
    <item>
      <title>Final Results</title>
      <link>https://6ix.com/company/proteome-sciences-plc/news/final-results-783</link>
      <guid isPermaLink="true">https://6ix.com/company/proteome-sciences-plc/news/final-results-783</guid>
      <pubDate>Thu, 10 Apr 2025 06:00:00 GMT</pubDate>
      <description>Final Results.</description>
    </item>
    <item>
      <title>Notice of Results and Investor Presentation</title>
      <link>https://6ix.com/company/proteome-sciences-plc/news/notice-of-results-and-investor-presentation-171</link>
      <guid isPermaLink="true">https://6ix.com/company/proteome-sciences-plc/news/notice-of-results-and-investor-presentation-171</guid>
      <pubDate>Fri, 04 Apr 2025 12:00:00 GMT</pubDate>
      <description>Notice of Results and Investor Presentation.</description>
    </item>
    <item>
      <title>Contract Win</title>
      <link>https://6ix.com/company/proteome-sciences-plc/news/contract-win-82</link>
      <guid isPermaLink="true">https://6ix.com/company/proteome-sciences-plc/news/contract-win-82</guid>
      <pubDate>Fri, 21 Feb 2025 07:00:00 GMT</pubDate>
      <description>Contract Win.</description>
    </item>
    <item>
      <title>Loan Facility, Trading Update &amp; Directorate Change</title>
      <link>https://6ix.com/company/proteome-sciences-plc/news/loan-facility-trading-update-and-directorate-change</link>
      <guid isPermaLink="true">https://6ix.com/company/proteome-sciences-plc/news/loan-facility-trading-update-and-directorate-change</guid>
      <pubDate>Mon, 23 Dec 2024 07:08:00 GMT</pubDate>
      <description>Loan Facility, Trading Update &amp; Directorate Change.</description>
    </item>
    <item>
      <title>Interim Results and Directorate Change</title>
      <link>https://6ix.com/company/proteome-sciences-plc/news/interim-results-and-directorate-change-1</link>
      <guid isPermaLink="true">https://6ix.com/company/proteome-sciences-plc/news/interim-results-and-directorate-change-1</guid>
      <pubDate>Fri, 13 Sep 2024 06:00:00 GMT</pubDate>
      <description>Interim Results and Directorate Change.</description>
    </item>
    <item>
      <title>AGM Statement</title>
      <link>https://6ix.com/company/proteome-sciences-plc/news/agm-statement-399</link>
      <guid isPermaLink="true">https://6ix.com/company/proteome-sciences-plc/news/agm-statement-399</guid>
      <pubDate>Thu, 16 May 2024 06:00:00 GMT</pubDate>
      <description>AGM Statement.</description>
    </item>
    <item>
      <title>Completion of new facility in San Diego</title>
      <link>https://6ix.com/company/proteome-sciences-plc/news/completion-of-new-facility-in-san-diego</link>
      <guid isPermaLink="true">https://6ix.com/company/proteome-sciences-plc/news/completion-of-new-facility-in-san-diego</guid>
      <pubDate>Tue, 02 Jan 2024 07:00:00 GMT</pubDate>
      <description>Completion of new facility in San Diego.</description>
    </item>
    <item>
      <title>Trading Update</title>
      <link>https://6ix.com/company/proteome-sciences-plc/news/trading-update-854</link>
      <guid isPermaLink="true">https://6ix.com/company/proteome-sciences-plc/news/trading-update-854</guid>
      <pubDate>Thu, 30 Nov 2023 07:00:00 GMT</pubDate>
      <description>Trading Update.</description>
    </item>
    <item>
      <title>Launch of Single Cell Proteomics Services</title>
      <link>https://6ix.com/company/proteome-sciences-plc/news/launch-of-single-cell-proteomics-services</link>
      <guid isPermaLink="true">https://6ix.com/company/proteome-sciences-plc/news/launch-of-single-cell-proteomics-services</guid>
      <pubDate>Mon, 02 Oct 2023 06:00:00 GMT</pubDate>
      <description>Launch of Single Cell Proteomics Services.</description>
    </item>
  </channel>
</rss>